A recent Kerala High Court proceeding has highlighted the financial barriers patients face when accessing essential breast cancer treatments. The case, which focuses on the high pricing of patented drugs ribociclib and abemaciclib, underscores the broader struggle for individuals lacking adequate insurance or financial support. Many patients are forced to weigh the necessity of life-saving care against their ability to afford prolonged treatment cycles. The court's involvement in addressing these exorbitant costs presents a significant opportunity for the central government to intervene and improve affordability. By examining the accessibility of these critical medications, the judiciary has brought national attention to the urgent need for policy reforms that ensure cancer patients are not compelled to discontinue their treatment due to prohibitive expenses.
Source : Scroll.in
Photo : Scroll.in
